Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.
about
Muscle atrophy in transgenic mice expressing a human TSC1 transgenemiR-31 modulates dystrophin expression: new implications for Duchenne muscular dystrophy therapyExon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation studyLocal restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept studyAntisense-mediated exon skipping: a versatile tool with therapeutic and research applicationsA chemical view of oligonucleotides for exon skipping and related drug applicationsAntisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistriesPhysico-chemical characteristics of lipoplexes influence cell uptake mechanisms and transfection efficacyTherapeutic Potential of Tricyclo-DNA antisense oligonucleotidesPrevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.Nanopolymers improve delivery of exon skipping oligonucleotides and concomitant dystrophin expression in skeletal muscle of mdx mice.Proteomic profiling of antisense-induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragm.Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.Evaluation of Tris[2-(acryloyloxy)ethyl]isocyanurate cross-linked polyethylenimine as antisense morpholino oligomer delivery vehicle in cell culture and dystrophic mdx miceDystrophin isoform induction in vivo by antisense-mediated alternative splicing.Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx miceGene knockdowns in adult animals: PPMOs and vivo-morpholinos.In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse.Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy.Mammalian models of Duchenne Muscular Dystrophy: pathological characteristics and therapeutic applications.Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice.Gene therapy progress and prospects: Duchenne muscular dystrophy.Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy.Induction of revertant fibres in the mdx mouse using antisense oligonucleotidesTreatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus.Therapeutic approaches to muscular dystrophy.Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.Antisense oligonucleotide induction of progerin in human myogenic cellsExon-skipping therapy: a roadblock, detour, or bump in the road?Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophyThe use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouse.Cationic polyelectrolyte-mediated delivery of antisense morpholino oligonucleotides for exon-skipping in vitro and in mdx mice.Multiple exon skipping strategies to by-pass dystrophin mutations.Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy.Modulating the expression of disease genes with RNA-based therapy.Novel compounds for the treatment of Duchenne muscular dystrophy: emerging therapeutic agentsImproved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle.Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies.Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophyMolecular-targeted therapy for Duchenne muscular dystrophy: progress and potential.
P2860
Q24304304-DE4DE806-EBE6-4651-B694-5ABDC7FB558FQ24608004-BDD2B27D-1C11-44B7-B83C-564EFF50A39CQ24616493-B47ECD13-350D-4DB6-8BBC-A6C0EFB577D2Q24643018-6C1AACC1-A0F9-45CE-B82C-89CCD11A4FA2Q24682555-6DCD412D-DCAB-4BB4-9D55-67A9CA16073EQ26863684-727EFA94-9363-447F-9FDB-7737EE2B37A5Q27480935-F4FA7271-0906-44FA-B71E-05419D630654Q28475692-E3729DEA-33D2-4C0E-A3E6-B1AB0662D6A7Q28818017-E7E72D4E-51BB-489C-92A3-B6C98B3374F4Q30493685-88723CAB-FF92-4B37-8F37-689487766BEBQ33326762-8BA513C3-7245-4860-B67D-9CD09C48D921Q33398588-1BE9243C-C401-4ED8-A068-7C779C327B24Q33573648-4E8B01F3-B3B8-45C5-A891-02FE1657352CQ33637696-CA753663-4C0D-4D4E-B050-D588AD4B9CFAQ33930110-71FA4B0F-E56D-43B3-9665-02A0BD5F52E6Q33931629-ABC62700-7528-41B3-AE52-1C513E21C881Q34016744-5A2A30C3-7D3D-48A0-9F0B-ACB2B1AAA185Q34343780-0C22D137-8AED-45A5-951C-1D5029EE7BA5Q34473309-975E5FB8-EA5F-42F5-ADAE-79AAAE78C9C9Q34497055-A94E4DFF-BC67-4399-B119-FE8A03F3C096Q34556906-5B952096-CD13-48D9-B9E0-A49E150F04EAQ34576814-FF1218EE-A306-438D-90E6-412E8579C42CQ34580135-652C7EDA-E551-493F-8E24-BFAE6E838049Q34691050-09CC813D-79CA-4F34-A063-C70415C1ACCDQ34787775-53C96AE5-4E37-46A5-ACDB-068E6714FEFFQ34982869-1AAF98B4-F133-4934-89B9-8C8874BD9A17Q34995170-39C0184B-83CF-4582-A10D-9AC2A77A330EQ35180565-FF371AE4-DE71-4071-9735-0B6E61D35C6CQ35731229-AFF202D7-3283-44D2-9375-F9559717C70BQ35750055-38E721CC-BB33-4697-B4ED-D014E048B142Q35881677-97AA9306-B5D4-4DE7-AA9D-AC297EBD8B6DQ36036988-F19F6740-40C1-4B0F-A8BA-3B358726D1FEQ36369845-801DEB30-5177-492E-B4C5-CBC82AF128F7Q36482835-6694174C-2B30-4A1F-AB7C-0E9B13909012Q36866549-614AB5A1-63BA-42FD-BE2F-130A4ABB52DFQ36925191-5877FC1C-8947-4558-9060-6342B85616FFQ36972091-9B656DF3-5891-4D29-8BB3-34776EB6643EQ36972120-AC1B8AB0-6154-4328-AD6F-37E6F760366DQ37105210-11BA1E35-9980-4056-A51F-660A4071E260Q37142004-E0F11D46-FEE3-4E63-A323-A5398848CC39
P2860
Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Dystrophin expression in the m ...... ino antisense oligonucleotide.
@ast
Dystrophin expression in the m ...... ino antisense oligonucleotide.
@en
type
label
Dystrophin expression in the m ...... ino antisense oligonucleotide.
@ast
Dystrophin expression in the m ...... ino antisense oligonucleotide.
@en
prefLabel
Dystrophin expression in the m ...... ino antisense oligonucleotide.
@ast
Dystrophin expression in the m ...... ino antisense oligonucleotide.
@en
P2093
P2860
P356
P1476
Dystrophin expression in the m ...... ino antisense oligonucleotide.
@en
P2093
Abbie M Fall
Kaite Honeyman
Penny L Harding
Russell D Johnsen
Steve D Wilton
Susan Fletcher
P2860
P304
P356
10.1002/JGM.838
P577
2006-02-01T00:00:00Z